BioSig (BSGM) 10-Q 1 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	1-May-15
Document and Entity Information [Abstract]
Entity Registrant Name	BIOSIG TECHNOLOGIES, INC.
Document Type	10-Q
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		13,634,961
Amendment Flag	FALSE
Entity Central Index Key	1530766
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash	$2,059,328	$239,781
Prepaid expenses	159,768	75,537
Total current assets	2,219,096	315,318
Property and equipment, net	12,844	13,020
Other assets:
Deposits	25,000	25,000
Total assets	2,256,940	353,338
Current liabilities:
Accounts payable and accrued expenses, including $14,605 and $40,293 to related parties as of March 31, 2015 and December 31, 2014 respectively	320,871	554,026
Stock based payable	646,066	226,305
Dividends payable	456,964	445,069
Warrant liability	4,097,444	0
Derivative liability	1,242,590	0
Total current liabilities	6,763,935	1,225,400
Series C 9% Convertible Preferred stock, 2,461 and 2,711 shares issued and outstanding, liquidation preference of $2,461,000 and $2,711,000, respectively	2,461,000	2,711,000
Stockholders' deficit
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B and 4,200 shares of Series C Preferred Stock	0	0
Common stock, $0.001 par value, authorized 50,000,000 shares, 13,159,694 and 11,179,266 issued and outstanding as of March 31, 2015 and December 31, 2014, respectively	13,160	11,179
Additional paid in capital	18,852,156	19,186,163
Accumulated deficit	-25,833,311	-22,780,404
Total stockholders' deficit	-6,967,995	-3,583,062
Total liabilities and stockholders' deficit	$2,256,940	$353,338

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parentheticals) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Accounts payable and accrued expenses, related parties (in Dollars)	$14,605	$40,293
Preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	13,159,694	11,179,266
Common stock, shares outstanding	13,159,694	11,179,266
Series C Preferred Stock [Member]
Preferred stock, Series C %	9.00%	9.00%
Preferred stock, shares issued	2,461	2,711
Preferred stock, shares outstanding	2,461	2,711
Preferred stock, liquidation preference (in Dollars)	$2,461,000	$2,711,000
Preferred stock, shares authorized	4,200	4,200
Series A Preferred Stock [Member]
Preferred stock, shares authorized	200	200
Series B Preferred Stock [Member]
Preferred stock, shares authorized	600	600

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Operating expenses:
Research and development	$302,079	$122,151
General and administrative	2,746,853	601,565
Depreciation	2,860	4,435
Total operating expenses	3,051,792	728,151
Loss from operations	-3,051,792	-728,151
Other income (expense):
Interest income (expense)	-1,114	-1,098
Financing costs	0	-388,285
Loss before income taxes	-3,052,906	-1,117,534
Income taxes (benefit)	0	0
Net loss	-3,052,906	-1,117,534
Preferred stock dividend	-79,395	-84,024
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	($3,132,301)	($1,201,558)
Net loss per common share, basic and diluted (in Dollars per share)	($0.26)	($0.14)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	12,256,418	8,482,710

CONDENSED_STATEMENT_OF_STOCKHO

CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT (unaudited) (USD $)	Warrant [Member]	Warrant [Member]	Series C Preferred Stock [Member]	Series C Preferred Stock [Member]	Series C Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit during Development Stage [Member]	Embedded Derivative Financial Instruments [Member]	Total
	Additional Paid-in Capital [Member]		Common Stock [Member]	Additional Paid-in Capital [Member]			Embedded Derivative Financial Instruments [Member]
Balance at Dec. 31, 2014						$11,179		$19,186,163	($22,780,404)		($3,583,062)
Balance (in Shares) at Dec. 31, 2014						11,179,266					11,179,266
Sale of common stock						1,399		3,040,814			3,042,213
Sale of common stock (in Shares)						1,398,760
Common stock issued upon conversion of Series C preferred stock and accrued dividends at $1.50 per share			212	317,288	317,500
Common stock issued upon conversion of Series C preferred stock and accrued dividends at $1.50 per share (in Shares)			211,668
Common stock issued for services						370		928,530			928,900
Common stock issued for services (in Shares)						370,000
Reclassify fair value of derivative liability from equity	-4,097,444	-4,097,444					-1,242,590			-1,242,590
Fair value of vested options								798,789			798,789
Preferred stock dividend								-79,395			-79,395
Net loss									-3,052,906		-3,052,906
Balance at Mar. 31, 2015						$13,160		$18,852,156	($25,833,311)		($6,967,995)
Balance (in Shares) at Mar. 31, 2015						13,159,694					13,159,694

CONDENSED_STATEMENT_OF_STOCKHO1

CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT (unaudited) (Parentheticals) (Series C Preferred Stock [Member], Common Stock [Member], USD $)	Mar. 31, 2015	Dec. 31, 2014	Jan. 09, 2013
Series C Preferred Stock [Member] | Common Stock [Member]
Conversion of preferred stock at	$1.50	$1.50	$1.50

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	($3,052,906)	($1,117,534)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	2,860	4,435
Amortization of debt discount	0	388,285
Equity based compensation	1,634,714	343,837
Changes in operating assets and liabilities:
Prepaid expenses	8,744	-3,924
Accounts payable	-233,155	-119,856
Stock based payable	419,761	0
Deferred rent payable	0	-1,006
Net cash used in operating activities	-1,219,982	-505,763
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	-2,684	0
Net cash used in investing activity	-2,684	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock	3,042,213	229,222
Net repayments of related party advances	0	-20,281
Net cash provided by financing activities	3,042,213	208,941
Net (decrease) increase in cash and cash equivalents	1,819,547	-296,822
Cash and cash equivalents, beginning of the period	239,781	302,187
Cash and cash equivalents, end of the period	2,059,328	5,365
Supplemental disclosures of cash flow information:
Cash paid during the period for interest	1,115	1,098
Cash paid during the period for income taxes	0	0
Series C Preferred Stock [Member]
Non-cash investing and financing activities:
Common stock issued upon conversion of Series C preferred stock and accrued dividends	317,500	0
Fair Value of Derivative and Warrant Liability [Member]
Non-cash investing and financing activities:
Reclassify fair value of derivative and warrant liability from equity	$5,440,034	$0

NOTE_1_SUMMARY_OF_SIGNIFICANT_

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	A summary of the significant accounting policies applied in the preparation of the accompanying financial statements follows.
	Business and organization
	BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.
	Interim Financial Statements
	The unaudited condensed interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.
	The condensed balance sheet as of December 31, 2014 has been derived from audited financial statements.
	Operating results for the three months ended March 31, 2015 are not necessarily indicative of results that may be expected for the year ending December 31, 2015. These condensed financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2014 filed with the Company’s Form 10-K with the Securities and Exchange Commission on February 20, 2015.
	Basis of presentation
	The Company's primary efforts are devoted to conducting research and development principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. In addition, the Company has stockholders' deficiencies at March 31, 2015 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company's research and development will be successfully completed or that any product will be approved or commercially viable.
	The above factors raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying condensed financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that may result from the outcome of this uncertainty.
	Use of estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
	Fair Value of Financial Instruments
	The Company’s short-term financial instruments, including cash, prepaid expenses and other assets, accounts payable and accrued expenses and other liabilities, consist primarily of instruments without extended maturities, the fair value of which, based on management’s estimates, reasonably approximate their book value. The fair value of the Company’s convertible securities is based on management estimates and reasonably approximates their book value.
	Derivative Instrument Liability
	The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2015 and December 31, 2014, the Company did not have any derivative instruments that were designated as hedges.
	Research and development costs
	The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $302,079  and $122,151 for the three months ended March 31, 2015 and 2014, respectively.
	Income Taxes
	The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.
	Net Income (loss) Per Common Share
	The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.  Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.
	The computation of basic and diluted loss per share as of March 31, 2015 and 2014 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.
	Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:
		March 31,		March 31,
		2015		2014
	Series A convertible preferred stock		-		501,089
	Series B convertible preferred stock		-		451,726
	Series C convertible preferred stock		1,640,667		1,854,019
	Options to purchase common stock		6,205,190		2,990,977
	Warrants to purchase common stock		7,561,820		4,353,831
	Totals		15,407,677		10,151,642
	Stock Based Compensation
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.
	As of March 31, 2015, the Company had 6,205,190 options outstanding to purchase shares of common stock, of which 4,130,240 were vested.
	As of December 31, 2014, the Company had 5,990,190 options outstanding to purchase shares of common stock, of which 3,799,559 were vested.
	Registration Rights
	The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations.  On June 23, 2014, the Company filed Form S-1/A became effective with the Securities and Exchange Commission.  As such, the Company determined that payments were due under its registration rights agreement and therefore accrued $55,620 as interest expense during the year ended December 31, 2014 for the liability under the registration rights agreements.
	Recent Accounting Pronouncements
	There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.

NOTE_2_PROPERTY_AND_EQUIPMENT

NOTE 2 - PROPERTY AND EQUIPMENT	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 2 – PROPERTY AND EQUIPMENT
	Property and equipment as of March 31, 2015 and December 31, 2014 is summarized as follows:
		March 31,			December 31,
		2015			2014
	Computer equipment	$	57,584		$	54,900
	Furniture and fixtures		7,803			7,803
	Subtotal		65,387			62,703
	Less accumulated depreciation		(52,543	)		(49,683	)
	Property and equipment, net	$	12,844		$	13,020
	Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.
	Depreciation expense was $2,860 and $4,435 for the three months ended March 31, 2015 and 2014, respectively.

NOTE_3_ACCOUNTS_PAYABLE_AND_AC

NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 3 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES
	Accounts payable and accrued expenses at March 31, 2015 and December 31, 2014 consist of the following:
		March 31,		December 31,
		2015		2014
	Accrued accounting and legal	$	71,952	$	190,767
	Accrued reimbursements		17,305		26,792
	Accrued consulting		82,935		16,334
	Accrued research and development expenses		42,409		93,407
	Accrued credit card obligations		4,735		13,278
	Accrued payroll		-		62,068
	Accrued liquidated damages		55,620		55,620
	Accrued office and other		5,915		29,093
	Accrued settlement related to arbitration		40,000		66,667
		$	320,871	$	554,026

NOTE_4_SERIES_C_9_CONVERTIBLE_

NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block Supplement [Abstract]
Preferred Stock [Text Block]	NOTE 4 – SERIES C 9% CONVERTIBLE PREFERRED STOCK
	On January 9,  2013, the Board of Directors authorized the issuance of up to 4,200 shares of Series C Convertible Preferred Stock (the “Series C Convertible Preferred Stock”).
	The Series C convertible preferred stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends ; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the Stated Value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative.  The holders of Series C preferred stock have no voting rights, however without the affirmative vote of all the holders of then outstanding shares of the Series C preferred stock, the Company cannot (a) alter or change adversely the powers, preferences or rights given to the Series C preferred stock or alter or amend the Certificate of Designation.
	Each share of Series C preferred stock is convertible, at the holder’s option, inclusive of any accrued and unpaid dividends, at conversion price of $1.50 (as reset).
	If, at any time while the Series C preferred stock is outstanding, the Company sells or grants any option to purchase or sells or grants any right to re-price, or otherwise disposes of or issues any common stock or common stock equivalents entitling any Person to acquire shares of Common Stock at an effective price per share that is lower than the then conversion price (“Base Conversion Price”), then the conversion price shall be reduced to equal the Base Conversion Price.  Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued.  During 2014, the resets provisions as described above resulted in the conversion price reset to $1.50.
	The Series C preferred stock contains triggering events which would require redemption at (i) the greater of 120% of the stated value of $1,000 or the product of the variable weighted average price of the Company’s common stock on the trading day immediately preceding the date of the triggering event and the stated value divided by the then conversion price or (ii) either (a) redeem each Series C preferred share for a redemption price, in shares of the Company’s common stock, equal to a number of shares equal to the (i) above divided by 75%.   The Company determined that certain of the defined triggering events were outside the Company’s control and therefore classified the Series C preferred stock outside of equity.
	In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 1,330,627 warrants to purchase the Company’s common stock at $2.61 per share expiring five years from the initial exercise date.  The warrant provides if, at any time while the warrant is outstanding, the Company sells or grants any option to purchase or sells or grants any right to re-price, or otherwise disposes of or issues any common stock or common stock equivalents entitling any person to acquire shares of common stock at an effective price per share that is lower than the then conversion price (“base conversion price”), then the conversion price shall be reduced to equal the Base Conversion Price.
	Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued.  In addition, the warrants provides for at any time after the six month anniversary of the initial exercise date, there is no effective registration statement registering, or no current prospectus available for the resale of the warrant shares by the holder, then the warrant may only be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the holder shall be entitled to receive a number of Warrant Shares equal to defined formula. During 2014, the resets provisions as described above resulted in an additional 984,674 warrants issued with an exercise price reset to $1.50 all Series C warrants.
	In accordance with ASC 470-20, the Company recognized an embedded beneficial conversion feature present in the Series C preferred stock when it was issued. The Company allocated the net proceeds between the intrinsic value of the conversion option ($1,303,671) and the warrants ($1,064,739) to additional paid-in capital.  The aggregate debt discount, comprised of the relative intrinsic value the conversion option ($1,303,671),  relative fair value of the warrants ($1,064,739), and the issuance costs ($412,590); total of $2,781,000, is amortized over one year as interest expense, the date a possible redemption feature, outside of the Company’s control, would be available to the Series C stockholders
	During the month of February 2013, the holders of previously issued convertible bridge notes converted into 600 shares of the Company’s Series C 9% Convertible Preferred Stock.
	During the months of February, March, May, and July 2013, the Company sold an aggregate of 2,181 shares of the Company’s Series C 9% Convertible Preferred Stock for net proceeds of $1,814,910.
	At the time of issuance and till March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C 9% Convertible Preferred Stock and related issued warrants did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation is not required.  There was no established market for the Company’s common stock.  As described in Note 6, March 31, 2015, the Company determined a market has been established for the Company’s common stock and accordingly, reclassified the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively, from equity to liabilities.
	As of March 31, 2015, the Company valued the reset provisions of the Series C Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: contractual terms of 2.78 to 3.50 years, a risk free interest rate of 0.56% to 0.89%, a dividend yield of 0%, and volatility of 141.00%.
	During January 2015, the Company issued an aggregate of 42,334 shares of its commons stock in exchange for 50 shares of the Company’s Series C 9% Convertible Preferred Stock and accrued dividends.
	During March 2015, the Company issued an aggregate of 169,334 shares of its commons stock in exchange for 200 shares of the Company’s Series C 9% Convertible Preferred Stock and accrued dividends.
	Series C preferred stock issued and outstanding totaled 2,461 and 2,711 as of March 31, 2015 and December 31, 2014, respectively.  As of March 31, 2015 and December 31, 2014, the Company has accrued $456,964 and $445,069 dividends payable on the Series C preferred stock.
	Registration Rights Agreement
	The Company entered into a Registration Rights Agreement  in connection with the sale and issuance of the Series C preferred stock.  The Company is required to file a registration statement registering for resale the  (a) common stock issuable upon conversion in full of the Preferred Stock (assuming on such date the shares of Preferred Stock are converted in full without regard to any conversion limitations therein), (b) all shares of Common Stock issuable as dividends and “Make-Whole Payments” (as defined in the Certificate of Designation) on the Preferred Stock assuming all dividend and Make-Whole Payments are made in shares of Common Stock and the Preferred Stock is held for at least 3 years, (c) all warrant shares then issuable upon exercise of the Warrants (assuming on such date the warrants are exercised in full without regard to any exercise limitations therein), (d) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the Preferred Stock or the Warrants (in each case, without giving effect to any limitations on conversion set forth in the Certificate of Designation or limitations on exercise set forth in the Warrants) and (e) any securities issued or then issuable upon any stock split, dividend or other distribution,  recapitalization or similar event with respect to the foregoing. The Company is required to file a registration statement and must be declared effective no later than 210 days from the date of termination of the sale the Series C preferred stock.
	The Company was required to maintain the effectiveness of the registration statement from its effective date unless all securities registered under the registration statement have been sold or are otherwise able to be sold.  If the Company failed to comply with the registration statement effective date requirements, the Company is required to pay the investors a fee equal to 0.25% of the Purchaser’s investment, for each 30-day period of delay, subject to a maximum payment of 3% to each Purchaser.
	On June 23 2014, the Company became effective and met its required filing requirement.  The Company did not meet the effectiveness obligation by November 22, 2013.  As a result, the Company accrued $55,620 as interest expense for liquidating damages due under the registration rights agreement.

NOTE_5_WARRANT_AND_DERIVATIVE_

NOTE 5 - WARRANT AND DERIVATIVE LIABILITIES	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Derivatives and Fair Value [Text Block]	NOTE 5 – WARRANT AND DERIVATIVE LIABILITIES
	At the time of issuance and till March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C 9% Convertible Preferred Stock and related warrants (see Note 5) did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation was not required.  There was no established market for the Company’s common stock.   As of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified from equity to liability treatment the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively. .
	The Company valued the reset provisions of the Series C Preferred Stock in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 0.56% to 0.89, a dividend yield of 0%, and volatility of 141.00%.

NOTE_6_STOCKHOLDER_EQUITY

NOTE 6 - STOCKHOLDER EQUITY	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 6 – STOCKHOLDER EQUITY
	Preferred stock
	The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of March 31, 2015 and December 31, 2014,  the Company has designated 200 shares of Series A preferred stock, 600 shares of Series B preferred stock and 4,200 , shares of Series C preferred stock.   As of March 31, 2015 and December 31, 2014, there were no outstanding shares of Series A and Series B preferred stock.
	During January 2015, the Company issued an aggregate of 42,334 shares of its commons stock in exchange for 50 shares of the Company’s Series C 9% Convertible preferred stock and accrued dividends.
	During March 2015, the Company issued an aggregate of 169,334 shares of its commons stock in exchange for 200 shares of the Company’s Series C 9% Convertible preferred stock and accrued dividends.
	As of March 31, 2015 and December 31, 2014, the Company has 2,461 and 2,711 Series C 9% Convertible Preferred Stock issued and outstanding.
	Common stock
	The Company is authorized to issue 50,000,000 shares of $0.001 par value common stock. As of March 31, 2015 and December 31, 2014, the Company has 13,159,694 and 11,179,266 shares issued and outstanding, respectively.
	During the three months ended March 31, 2015, the Company issued an aggregate of 370,000 shares of common stock under the terms of its 2012 Equity Plan for services rendered totaling $928,900 ($2.51 average per share).
	During the three months ended March 31, 2015, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 1,398,760 shares of common stock and warrants for aggregate net proceeds of $3,042,213.
	In connection with the securities purchase agreements described above, the Company entered into a registration rights agreement whereas the Company is required to file a registration statement registering for resale the  a) all of the purchase agreement Shares, (b) all investor warrant Shares then issuable upon exercise of the investor warrants, (c)  the shares of common stock underlying the investment banker warrants; (d) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the investor warrants and the investment banker warrants (e) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing. The Company is required to file a registration statement the 45 days following the final closing date and must be declared effective no later than 180 days from the filing date.
	The Company was required to maintain the effectiveness of the registration statement from its effective date unless all securities registered under the registration statement have been sold or are otherwise able to be sold.  If the Company failed to comply with the registration statement filing and effective date requirements, the Company is required to pay the investors a fee equal to 1% of the Purchaser’s investment, for each 30-day period of delay, subject to a maximum payment of 6% to each Purchaser.
	Stock based payable
	The Company is obligated to issue shares of its common stock to board members and consultants for past and future services.  The estimated liability as of March 31, 2015 and December 31, 2014 of $646,066 and $226,305 was determined based on services rendered  for past services as of March 31, 2015 and December 31, 2014, respectively.
	As of March 31, 2015, the Company is obligated to issue an aggregate of 352,500 shares of its common stock.  These shares were considered issued as of the date of obligation in determining the weighted average number of outstanding shares used in the basic loss per common share calculation.

NOTE_7_OPTIONS_AND_WARRANTS

NOTE 7 - OPTIONS AND WARRANTS	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	NOTE 7 – OPTIONS AND WARRANTS
	On October 19, 2012, the Company’s Board of Directors approved the 2012 Equity Incentive Plan (“the “2012 Plan) and terminated the Long-Term Incentive Plan (the “2011 Plan”). The Plan provides for the issuance of options to purchase up to 8,806,123,( as amended)  shares of the Company’s common stock to officers, directors, employees and consultants of the Company (as amended). Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company determines the exercise price, vesting and expiration period of the grants under the Plan. However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on quoted market price or in absence of such quoted market price, by the Board of Directors in good faith.
	Additionally, the vesting period of the grants under the Plan will be determined by the Committee, in its sole discretion, and expiration period not more than ten years. The Company reserved 1,250,000 shares of its common stock for future issuance under the terms of the Plan.
	During the three months ended March 31, 2015, the Company granted an aggregate of 200,000 options and 370,000 stock grants to officers, directors and key consultants.
	The following table presents information related to stock options at March 31, 2015:
	Options Outstanding												Options Exercisable
									Weighted
									Average				Exercisable
	Exercise				Number of				Remaining Life				Number of
	Price				Options				In Years				Options
	$	1.01-2.00				834,642				4.5				541,642
		2.01-2.50				5,370,548				6.7				3,588,598
						6,205,190				6.4				4,130,240
	A summary of the stock option activity and related information for the 2012 Plan for the three months ended March 31, 2015 is as follows:
											Weighted-Average
							Weighted-Average				Remaining				Aggregate
			Shares				Exercise Price				Contractual Term				Intrinsic Value
	Outstanding at January 1, 2015			5,990,190			$	2.25				6.7				3,267,692
	Grants			215,000				2.47				7				-
	Exercised
	Canceled
	Outstanding at March 31, 2015			6,205,190			$	2.26				6.4			$	1,098,888
	Exercisable at March 31, 2015			4,130,240			$	2.25				5.9			$	797,753
	The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s estimated market stock price of $2.40 as of March 31, 2015, which would have been received by the option holders had those option holders exercised their options as of that date.
	Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data exists to estimate the volatility using the Company’s own historical stock prices. Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.  The fair value of stock-based payment awards during the three months ended March 31, 2015 was estimated using the Black-Scholes pricing model.
	In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the number of vested options as a percentage of total options outstanding.
	If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period.
	The Company estimated forfeitures related to option grants at a weighted average annual rate of  0% per year, as the Company does not yet have adequate historical data, for options granted during the three months ended March 31, 2015.
	During the months ended March 31, 2015, the Company granted an aggregate of 215,000 options to purchase the Company stock in connection with the services rendered at the exercise prices from $2.00 to $2.50 per share for a term of seven years with 15,000 vesting immediately and 200,000 over two years at 50% for the first and second anniversary.
	The fair value of the granted options for three months ended March 31, 2015 was determined using the Black Scholes option pricing model with the following assumptions:
	Dividend yield:			-0-	%
	Volatility		129.54% to 130.30		%
	Risk free rate:		1.19% to 1.79		%
	Expected life:		7 years
	Estimated fair value of the Company’s common stock		$	1.99 to $2.24
	Estimated forfeiture rate			0	%
	The fair value of all options vesting during the three months ended March 31, 2015 and 2014 of $798,789 and $343,837, respectively, was charged to current period operations.  Unrecognized compensation expense of $1,970,428 at March 31, 2015 will be expensed in future periods.
	Warrants
	The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company, all of which were exercisable, at December 31, 2014:
	Exercise				Number			Expiration
	Price				Outstanding			Date
	$	0.001				383,320		Jan-20
	$	1.5				3,721,518		February 2018 to September 2018
	$	1.84				35,076		Jan-20
	$	2.02				30,755		Jan-20
	$	2.5				1,603,600		Jul-15
	$	2.75				228,720		August 2019 to September 2019
	$	3.67				218,275		December 2018 to January 2019
	$	3.75				1,340,556		April 2019 to March 2020
						7,561,820
	On January 23, 2015, the Company issued an aggregate of 428,400 and 321,300 warrants to purchase the Company’s common stock at $2.50 and $3.75 per share, respectively, expiring on July 31, 2015 and March 31, 2020, respectively, in connection with the sale of the Company’s common stock.
	On February 10, 2015, the Company issued an aggregate of 337,000 and 252,750 warrants to purchase the Company’s common stock at $2.50 and $3.75 per share, respectively, expiring on July 31, 2015 and March 31, 2020, respectively, in connection with the sale of the Company’s common stock.
	On February 27, 2015, the Company issued an aggregate of 223,000 and 167,250 warrants to purchase the Company’s common stock at $2.50 and $3.75 per share, respectively, expiring on July 31, 2015 and March 31, 2020, respectively, in connection with the sale of the Company’s common stock.
	On March 31, 2015, the Company issued an aggregate of 410,360 and 307,770 warrants to purchase the Company’s common stock at $2.50 and $3.75 per share, respectively, expiring on July 31, 2015 and March 31, 2020, respectively, in connection with the sale of the Company’s common stock.
	A summary of the warrant activity for the three months ended March 31, 2015 is as follows:
											Weighted-Average
							Weighted-Average				Remaining				Aggregate
			Shares				Exercise Price				Contractual Term				Intrinsic Value
	Outstanding at January 1, 2015			5,113,990			$	1.71				3.6				6,041,436
	Grants			2,447,830				3.04				2.4				-
	Exercised
	Canceled
	Outstanding at March 31, 2015			7,561,820			$	2.14				3			$	4,300,280
	Vested and expected to vest at March 31, 2015			7,561,820			$	2.14				3			$	4,300,280
Exercisable at March 31, 2015			7,561,820			$	2.14				3			$	4,300,280
The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s estimated market stock price of $2.40 as of March 31, 2015, which would have been received by the option holders had those option holders exercised their options as of that date.

NOTE_8_FAIR_VALUE_MEASUREMENT

NOTE 8 - FAIR VALUE MEASUREMENT	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 8 – FAIR VALUE MEASUREMENT
	The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:
	Level 1 – Quoted prices in active markets for identical assets or liabilities.
	Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.
	All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.
	To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.
	Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.
	The carrying value of the Company’s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity.
	As of March 31, 2015 or December 31, 2014, the Company did not have any items that would be classified as level 1 or 2 disclosures.
	The Company recognizes its derivative and warrant liabilities as level 3 and values its derivatives using the methods discussed in Note 6. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Note 6 are that of volatility and market price of the underlying common stock of the Company.
	As of March 31, 2015 and December 31, 2014, the Company did not have any derivative instruments that were designated as hedges.
	The derivative and warrant liability as of March 31, 2015, in the amount of $1,242,590 and $4,097,444 has a level 3 classification, respectively.
	The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of March 31, 2015:
		Warrant		Derivative
		Liability
	Balance, December 31, 2014	$	-	$	-
	Total (gains) losses
	Initial fair value of derivative at March 31, 2015, reclassified from equity		—		1,242,590
	Initial fair value of warrant liability at March 31, 2015, reclassified from equity		4,097,444		—
	Balance, March 31, 2015	$	4,097,444	$	1,242,590
	Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. As the stock price increases for each of the related derivative instruments, the value to the holder of the instrument generally increases, therefore increasing the liability on the Company’s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments.

NOTE_9_SUBSEQUENT_EVENTS

NOTE 9 - SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 9 – SUBSEQUENT EVENTS
	On April 9, 2015, the Company granted options to acquire 300,000 shares of its common stock at an exercise price of $3.99 for seven years, vesting immediately upon appointment of a new board of directors member.
	In April 2015, the Company issued an aggregate of 131,234 shares of its common stock in exchange for 155 shares of Series C 9% Convertible preferred stock and accrued dividends.
	In April 2015, the Company issued 84,033 shares of its common stock in exchange for the exercise of 130,084 warrants exercisable at $1.50, on a cashless basis.
	In April 2015, the Company issued an aggregate of 200,000 shares of its common stock to board of directors for services rendered.
	In April 2015, the Company issued 50,000 shares of its common stock to a consultant for services rendered.
	In April 2015, the Company issued an aggregate of 10,000 shares of its common stock for the exercise of  previously issued options  at $2.09 per share.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Business and organization
	BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.
	Interim Financial Statements
	The unaudited condensed interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.
	The condensed balance sheet as of December 31, 2014 has been derived from audited financial statements.
	Operating results for the three months ended March 31, 2015 are not necessarily indicative of results that may be expected for the year ending December 31, 2015. These condensed financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2014 filed with the Company’s Form 10-K with the Securities and Exchange Commission on February 20, 2015.
	Basis of presentation
	The Company's primary efforts are devoted to conducting research and development principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. In addition, the Company has stockholders' deficiencies at March 31, 2015 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company's research and development will be successfully completed or that any product will be approved or commercially viable.
	The above factors raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying condensed financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that may result from the outcome of this uncertainty.
Use of Estimates, Policy [Policy Text Block]	Use of estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments
	The Company’s short-term financial instruments, including cash, prepaid expenses and other assets, accounts payable and accrued expenses and other liabilities, consist primarily of instruments without extended maturities, the fair value of which, based on management’s estimates, reasonably approximate their book value. The fair value of the Company’s convertible securities is based on management estimates and reasonably approximates their book value.
Derivatives, Policy [Policy Text Block]	Derivative Instrument Liability
	The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2015 and December 31, 2014, the Company did not have any derivative instruments that were designated as hedges.
Research and Development Expense, Policy [Policy Text Block]	Research and development costs
	The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $302,079  and $122,151 for the three months ended March 31, 2015 and 2014, respectively.
Income Tax, Policy [Policy Text Block]	Income Taxes
	The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.
Earnings Per Share, Policy [Policy Text Block]	Net Income (loss) Per Common Share
	The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.  Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.
	The computation of basic and diluted loss per share as of March 31, 2015 and 2014 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.
	Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:
		March 31,		March 31,
		2015		2014
	Series A convertible preferred stock		-		501,089
	Series B convertible preferred stock		-		451,726
	Series C convertible preferred stock		1,640,667		1,854,019
	Options to purchase common stock		6,205,190		2,990,977
	Warrants to purchase common stock		7,561,820		4,353,831
	Totals		15,407,677		10,151,642
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Based Compensation
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.
	As of March 31, 2015, the Company had 6,205,190 options outstanding to purchase shares of common stock, of which 4,130,240 were vested.
	As of December 31, 2014, the Company had 5,990,190 options outstanding to purchase shares of common stock, of which 3,799,559 were vested.
Registration Rights Policy [Policy Text Block]	Registration Rights
	The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations.  On June 23, 2014, the Company filed Form S-1/A became effective with the Securities and Exchange Commission.  As such, the Company determined that payments were due under its registration rights agreement and therefore accrued $55,620 as interest expense during the year ended December 31, 2014 for the liability under the registration rights agreements.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements
	There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.

NOTE_1_SUMMARY_OF_SIGNIFICANT_1

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:
		March 31,		March 31,
		2015		2014
	Series A convertible preferred stock		-		501,089
	Series B convertible preferred stock		-		451,726
	Series C convertible preferred stock		1,640,667		1,854,019
	Options to purchase common stock		6,205,190		2,990,977
	Warrants to purchase common stock		7,561,820		4,353,831
	Totals		15,407,677		10,151,642

NOTE_2_PROPERTY_AND_EQUIPMENT_

NOTE 2 - PROPERTY AND EQUIPMENT (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of March 31, 2015 and December 31, 2014 is summarized as follows:
		March 31,			December 31,
		2015			2014
	Computer equipment	$	57,584		$	54,900
	Furniture and fixtures		7,803			7,803
	Subtotal		65,387			62,703
	Less accumulated depreciation		(52,543	)		(49,683	)
	Property and equipment, net	$	12,844		$	13,020

NOTE_3_ACCOUNTS_PAYABLE_AND_AC1

NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Accounts payable and accrued expenses at March 31, 2015 and December 31, 2014 consist of the following:
		March 31,		December 31,
		2015		2014
	Accrued accounting and legal	$	71,952	$	190,767
	Accrued reimbursements		17,305		26,792
	Accrued consulting		82,935		16,334
	Accrued research and development expenses		42,409		93,407
	Accrued credit card obligations		4,735		13,278
	Accrued payroll		-		62,068
	Accrued liquidated damages		55,620		55,620
	Accrued office and other		5,915		29,093
	Accrued settlement related to arbitration		40,000		66,667
		$	320,871	$	554,026

NOTE_7_OPTIONS_AND_WARRANTS_Ta

NOTE 7 - OPTIONS AND WARRANTS (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block Supplement [Abstract]
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table presents information related to stock options at March 31, 2015:
	Options Outstanding												Options Exercisable
									Weighted
									Average				Exercisable
	Exercise				Number of				Remaining Life				Number of
	Price				Options				In Years				Options
	$	1.01-2.00				834,642				4.5				541,642
		2.01-2.50				5,370,548				6.7				3,588,598
						6,205,190				6.4				4,130,240
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the stock option activity and related information for the 2012 Plan for the three months ended March 31, 2015 is as follows:
											Weighted-Average
							Weighted-Average				Remaining				Aggregate
			Shares				Exercise Price				Contractual Term				Intrinsic Value
	Outstanding at January 1, 2015			5,990,190			$	2.25				6.7				3,267,692
	Grants			215,000				2.47				7				-
	Exercised
	Canceled
	Outstanding at March 31, 2015			6,205,190			$	2.26				6.4			$	1,098,888
	Exercisable at March 31, 2015			4,130,240			$	2.25				5.9			$	797,753
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of the granted options for three months ended March 31, 2015 was determined using the Black Scholes option pricing model with the following assumptions:
	Dividend yield:			-0-	%
	Volatility		129.54% to 130.30		%
	Risk free rate:		1.19% to 1.79		%
	Expected life:		7 years
	Estimated fair value of the Company’s common stock		$	1.99 to $2.24
	Estimated forfeiture rate			0	%
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]	The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company, all of which were exercisable, at December 31, 2014:
	Exercise				Number			Expiration
	Price				Outstanding			Date
	$	0.001				383,320		Jan-20
	$	1.5				3,721,518		February 2018 to September 2018
	$	1.84				35,076		Jan-20
	$	2.02				30,755		Jan-20
	$	2.5				1,603,600		Jul-15
	$	2.75				228,720		August 2019 to September 2019
	$	3.67				218,275		December 2018 to January 2019
	$	3.75				1,340,556		April 2019 to March 2020
						7,561,820
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of the warrant activity for the three months ended March 31, 2015 is as follows:
											Weighted-Average
							Weighted-Average				Remaining				Aggregate
			Shares				Exercise Price				Contractual Term				Intrinsic Value
	Outstanding at January 1, 2015			5,113,990			$	1.71				3.6				6,041,436
	Grants			2,447,830				3.04				2.4				-
	Exercised
	Canceled
	Outstanding at March 31, 2015			7,561,820			$	2.14				3			$	4,300,280
	Vested and expected to vest at March 31, 2015			7,561,820			$	2.14				3			$	4,300,280
	Exercisable at March 31, 2015			7,561,820			$	2.14				3			$	4,300,280

NOTE_8_FAIR_VALUE_MEASUREMENT_

NOTE 8 - FAIR VALUE MEASUREMENT (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of March 31, 2015:
		Warrant		Derivative
		Liability
	Balance, December 31, 2014	$	-	$	-
	Total (gains) losses
	Initial fair value of derivative at March 31, 2015, reclassified from equity		—		1,242,590
	Initial fair value of warrant liability at March 31, 2015, reclassified from equity		4,097,444		—
	Balance, March 31, 2015	$	4,097,444	$	1,242,590

NOTE_1_SUMMARY_OF_SIGNIFICANT_2

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Research and Development Expense (in Dollars)	$302,079	$122,151
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	6,205,190		5,990,190
Registration Payment Arrangement, Accrual Carrying Value (in Dollars)	$55,620		$55,620
Employee Stock Option [Member]
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	6,205,190		5,990,190
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	4,130,240		3,799,559

NOTE_1_SUMMARY_OF_SIGNIFICANT_3

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	15,407,677	10,151,642
Series A Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	0	501,089
Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	0	451,726
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	1,640,667	1,854,019
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	6,205,190	2,990,977
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	7,561,820	4,353,831

NOTE_2_PROPERTY_AND_EQUIPMENT_1

NOTE 2 - PROPERTY AND EQUIPMENT (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
NOTE 2 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Depreciation	$2,860	$4,435
Minimum [Member]
NOTE 2 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
NOTE 2 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life	5 years

NOTE_2_PROPERTY_AND_EQUIPMENT_2

NOTE 2 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment (USD $)	Mar. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$65,387	$62,703
Less accumulated depreciation	-52,543	-49,683
Property and equipment, net	12,844	13,020
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	57,584	54,900
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$7,803	$7,803

NOTE_3_ACCOUNTS_PAYABLE_AND_AC2

NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities (USD $)	Mar. 31, 2015	Dec. 31, 2014
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Accrued accounting and legal	$71,952	$190,767
Accrued reimbursements	17,305	26,792
Accrued consulting	82,935	16,334
Accrued research and development expenses	42,409	93,407
Accrued credit card obligations	4,735	13,278
Accrued payroll	0	62,068
Accrued liquidated damages	55,620	55,620
Accrued office and other	5,915	29,093
Accrued settlement related to arbitration	40,000	66,667
	$320,871	$554,026

NOTE_4_SERIES_C_9_CONVERTIBLE_1

NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) (USD $)	3 Months Ended	12 Months Ended	0 Months Ended		1 Months Ended		6 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2013	Feb. 06, 2013	Jan. 09, 2013	Mar. 31, 2015	Jan. 31, 2015	Jul. 31, 2013	Dec. 31, 2014
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Class of Warrant or Rights, Granted	2,447,830
Temporary Equity, Amortization Period		1 year
Embedded Derivative, Fair Value of Embedded Derivative Liability	$1,242,590				$1,242,590			$0
Derivative Liability, Current	4,097,444				4,097,444			0
Dividends Payable, Current	456,964				456,964			445,069
Registration Payment Arrangement, Term	The Company entered into a Registration Rights Agreement in connection with the sale and issuance of the Series C preferred stock. The Company is required to file a registration statement registering for resale the (a) common stock issuable upon conversion in full of the Preferred Stock (assuming on such date the shares of Preferred Stock are converted in full without regard to any conversion limitations therein), (b) all shares of Common Stock issuable as dividends and “Make-Whole Payments” (as defined in the Certificate of Designation) on the Preferred Stock assuming all dividend and Make-Whole Payments are made in shares of Common Stock and the Preferred Stock is held for at least 3 years, (c) all warrant shares then issuable upon exercise of the Warrants (assuming on such date the warrants are exercised in full without regard to any exercise limitations therein), (d) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the Preferred Stock or the Warrants (in each case, without giving effect to any limitations on conversion set forth in the Certificate of Designation or limitations on exercise set forth in the Warrants) and (e) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing. The Company is required to file a registration statement and must be declared effective no later than 210 days from the date of termination of the sale the Series C preferred stock.The Company was required to maintain the effectiveness of the registration statement from its effective date unless all securities registered under the registration statement have been sold or are otherwise able to be sold. If the Company failed to comply with the registration statement effective date requirements, the Company is required to pay the investors a fee equal to 0.25% of the Purchaser’s investment, for each 30-day period of delay, subject to a maximum payment of 3% to each Purchaser.
Registration Payment Arrangement, Accrual Carrying Value	55,620				55,620			55,620
Options Held [Member] | Series C Preferred Stock [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Adjustments to Additional Paid in Capital, Other		1,303,671
Temporary Equity, Liquidation Preference		1,303,671
Warrant [Member] | Series C Preferred Stock [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Adjustments to Additional Paid in Capital, Warrant Issued		1,064,739
Temporary Equity, Liquidation Preference		1,064,739
Issuance Costs [Member] | Series C Preferred Stock [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Temporary Equity, Liquidation Preference		412,590
Series C Preferred Stock [Member] | Common Stock [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Temporary Equity, Redemption Price Per Share	$1.50			$1.50	$1.50			$1.50
Series C Preferred Stock [Member] | Dividend Declared [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Dividends Payable, Current	456,964				456,964			445,069
Series C Preferred Stock [Member] | Bridge Loan [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued			600
Series C Preferred Stock [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Temporary Equity, Shares Authorized	4,200			4,200	4,200
Preferred Stock, Dividend Rate, Percentage	9.00%			9.00%				9.00%
Temporary Equity, Par Value				1,000
Preferred Stock, Dividend Payment Terms				payable quarterly
Preferred Stock, Voting Rights				no voting rights, however without the affirmative vote of all the holders of then outstanding shares of the Series C preferred stock, the Company cannot (a) alter or change adversely the powers, preferences or rights given to the Series C preferred stock or alter or amend the Certificate of Designation
Preferred Stock, Redemption Terms				(i) the greater of 120% of the stated value of $1,000 or the product of the variable weighted average price of the Company’s common stock on the trading day immediately preceding the date of the triggering event and the stated value divided by the then conversion price or (ii) either (a) redeem each Series C preferred share for a redemption price, in shares of the Company’s common stock, equal to a number of shares equal to the (i) above divided by 75%.
Class of Warrant or Rights, Granted				1,330,627				984,674
Class of Warrant or Right, Exercise Price of Warrants or Rights				$2.61				$1.50
Warrants, Term of Warrants				5 years
Warrant, Description of Warrant				after the six month anniversary of the initial exercise date, there is no effective registration statement registering, or no current prospectus available for the resale of the warrant shares by the holder, then the warrant may only be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the holder shall be entitled to receive a number of Warrant Shares equal to defined formula.
Temporary Equity, Liquidation Preference	2,461,000	2,781,000			2,461,000			2,711,000
Stock Issued During Period, Shares, New Issues							2,181
Proceeds from Issuance of Redeemable Preferred Stock							$1,814,910
Conversion of Stock, Shares Issued					169,334	42,334
Conversion of Stock, Shares Converted					200	50
Temporary Equity, Shares Issued	2,461				2,461			2,711
Temporary Equity, Shares Outstanding	2,461				2,461			2,711
Common Stock [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	1,398,760
Embedded Derivative Financial Instruments [Member] | Minimum [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Expected Term	2 years 284 days
Fair Value Assumptions, Risk Free Interest Rate	0.56%
Embedded Derivative Financial Instruments [Member] | Maximum [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Expected Term	3 years 6 months
Fair Value Assumptions, Risk Free Interest Rate	0.89%
Embedded Derivative Financial Instruments [Member]
NOTE 4 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Expected Dividend Rate	0.00%
Fair Value Assumptions, Expected Volatility Rate	141.00%

NOTE_5_WARRANT_AND_DERIVATIVE_1

NOTE 5 - WARRANT AND DERIVATIVE LIABILITIES (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
NOTE 5 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)	1,242,590	$0
Derivative Liability, Current (in Dollars)	4,097,444	$0
Embedded Derivative Financial Instruments [Member] | Minimum [Member]
NOTE 5 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate	0.56%
Embedded Derivative Financial Instruments [Member] | Maximum [Member]
NOTE 5 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate	0.89%
Embedded Derivative Financial Instruments [Member]
NOTE 5 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Expected Dividend Rate	0.00%
Fair Value Assumptions, Expected Volatility Rate	141.00%

NOTE_6_STOCKHOLDER_EQUITY_Deta

NOTE 6 - STOCKHOLDER EQUITY (Details) (USD $)	3 Months Ended	1 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 31, 2015	Jan. 31, 2015	Jul. 31, 2013	Dec. 31, 2014	Jan. 09, 2013
NOTE 6 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized	1,000,000	1,000,000			1,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)	$0.00	0.001			$0.00
Common Stock, Shares Authorized	50,000,000	50,000,000			50,000,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$0.00	0.001			$0.00
Common Stock, Shares, Issued	13,159,694	13,159,694			11,179,266
Common Stock, Shares, Outstanding	13,159,694	13,159,694			11,179,266
Stock Issued During Period, Value, Issued for Services (in Dollars)	$928,900
Proceeds from Issuance or Sale of Equity (in Dollars)	3,042,213
Deferred Compensation Liability, Current (in Dollars)	646,066	646,066			226,305
Common Stock, Shares Subscribed but Unissued	352,500	352,500
Series A Preferred Stock [Member]
NOTE 6 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized	200	200			200
Preferred Stock, Shares Issued	0	0			0
Series B Preferred Stock [Member]
NOTE 6 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized	600	600			600
Preferred Stock, Shares Outstanding	0	0			0
Series C Preferred Stock [Member]
NOTE 6 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized	4,200	4,200			4,200
Temporary Equity, Shares Authorized	4,200	4,200				4,200
Conversion of Stock, Shares Issued		169,334	42,334
Conversion of Stock, Shares Converted		200	50
Temporary Equity, Shares Issued	2,461	2,461			2,711
Temporary Equity, Shares Outstanding	2,461	2,461			2,711
Stock Issued During Period, Shares, New Issues				2,181
Private Placement [Member]
NOTE 6 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	1,398,760
Securities Purchase Agreement	In connection with the securities purchase agreements described above, the Company entered into a registration rights agreement whereas the Company is required to file a registration statement registering for resale the a) all of the purchase agreement Shares, (b) all investor warrant Shares then issuable upon exercise of the investor warrants, (c) the shares of common stock underlying the investment banker warrants; (d) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the investor warrants and the investment banker warrants (e) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing. The Company is required to file a registration statement the 45 days following the final closing date and must be declared effective no later than 180 days from the filing date.The Company was required to maintain the effectiveness of the registration statement from its effective date unless all securities registered under the registration statement have been sold or are otherwise able to be sold. If the Company failed to comply with the registration statement filing and effective date requirements, the Company is required to pay the investors a fee equal to 1% of the Purchaser’s investment, for each 30-day period of delay, subject to a maximum payment of 6% to each Purchaser.
Directors and Key Consultants [Member] | 2012 Equity Incentive Plan [Member]
NOTE 6 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services	370,000
Stock Issued During Period, Value, Issued for Services (in Dollars)	$928,900
Shares Issued, Price Per Share (in Dollars per share)	$2.51	2.51

NOTE_7_OPTIONS_AND_WARRANTS_De

NOTE 7 - OPTIONS AND WARRANTS (Details) (USD $)	3 Months Ended	0 Months Ended				3 Months Ended	0 Months Ended
	Mar. 31, 2015	Mar. 31, 2015	Feb. 27, 2015	Feb. 10, 2015	Jan. 23, 2015	Mar. 31, 2014	Oct. 19, 2012
NOTE 7 - OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	215,000
Class of Warrant or Rights, Granted	2,447,830
Directors and Key Consultants [Member] | 2012 Equity Incentive Plan [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	200,000
Stock Issued During Period, Shares, Issued for Services	370,000
Private Placement [Member] | Warrants at $2.50 [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted		410,360	223,000	337,000	428,400
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	2.5	$2.50	$2.50	$2.50	$2.50
Warrant, Expriation Date		31-Jul-15	31-Jul-15	31-Jul-15	31-Jul-15
Private Placement [Member] | Warrants at $3.75 [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted		307,770	167,250	252,750	321,300
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	3.75	$3.75	$3.75	$3.75	$3.75
Warrant, Expriation Date		31-Mar-20	31-Mar-20	31-Mar-20	31-Mar-20
Private Placement [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) [Line Items]
Share Price (in Dollars per share)	2.4	$2.40
Employee Stock Option [Member] | Share-based Compensation Award, Tranche One [Member] | 2012 Equity Incentive Plan [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	15,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	vesting immediately
Employee Stock Option [Member] | Share-based Compensation Award, Tranche Two [Member] | 2012 Equity Incentive Plan [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	2 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	50% for the first and second anniversary
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares	200,000	200,000
Employee Stock Option [Member] | Maximum [Member] | 2012 Equity Incentive Plan [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)	2.5	$2.50
Employee Stock Option [Member] | Minimum [Member] | 2012 Equity Incentive Plan [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	7 years
Employee Stock Option [Member] | 2012 Equity Incentive Plan [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) [Line Items]
Share Price (in Dollars per share)	2.4	$2.40
Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Forfeiture Rate	0.00%
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)	2	$2
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights						$343,837
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars)	798,789
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)	1,970,428	$1,970,428
Warrants at $2.50 [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	2.5	$2.50
Warrants at $3.75 [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	3.75	$3.75
Maximum [Member] | 2012 Equity Incentive Plan [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period							10 years
Maximum [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) [Line Items]
Share Price (in Dollars per share)	2.24	$2.24
Minimum [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) [Line Items]
Share Price (in Dollars per share)	1.99	$1.99
2012 Equity Incentive Plan [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							8,806,123
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award							However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder.
Common Stock, Capital Shares Reserved for Future Issuance							1,250,000

NOTE_7_OPTIONS_AND_WARRANTS_De1

NOTE 7 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number of Options	6,205,190	5,990,190
Options Outstanding, Weighted Average Remaining Life	6 years 146 days	6 years 255 days
Options Exercisable, Number of Options	4,130,240
Options at $1.01-2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	1.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	2
Options Outstanding, Number of Options	834,642
Options Outstanding, Weighted Average Remaining Life	4 years 6 months
Options Exercisable, Number of Options	541,642
Options at $2.01-2.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	2.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	2.5
Options Outstanding, Number of Options	5,370,548
Options Outstanding, Weighted Average Remaining Life	6 years 255 days
Options Exercisable, Number of Options	3,588,598

NOTE_7_OPTIONS_AND_WARRANTS_De2

NOTE 7 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Schedule of Share-based Compensation, Stock Options, Activity [Abstract]
Options Outstanding, Shares (in Shares)	6,205,190	5,990,190
Options Outstanding, Weighted-Average Exercise Price	$2.26	$2.25
Options Outstanding, Weighted-Average Remaining Contractual Term	6 years 146 days	6 years 255 days
Options Outstanding, Aggregate Intrinsic Value (in Dollars)	$1,098,888	$3,267,692
Exercisable at March 31, 2015 (in Shares)	4,130,240
Exercisable at March 31, 2015	$2.25
Exercisable at March 31, 2015	5 years 328 days
Exercisable at March 31, 2015 (in Dollars)	$797,753
Grants (in Shares)	215,000
Grants	$2.47
Grants	7 years
Grants	$0
Exercised (in Shares)	0
Exercised	$0
Canceled (in Shares)	0
Canceled	$0

NOTE_7_OPTIONS_AND_WARRANTS_De3

NOTE 7 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (USD $)	3 Months Ended
	Mar. 31, 2015
NOTE 7 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Dividend yield:	0.00%
Expected life:	7 years
Estimated forfeiture rate	0.00%
Minimum [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Volatility	129.54%
Risk free rate:	1.19%
Estimated fair value of the Companybs common stock (in Dollars per share)	1.99
Maximum [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Volatility	130.30%
Risk free rate:	1.79%
Estimated fair value of the Companybs common stock (in Dollars per share)	2.24

NOTE_7_OPTIONS_AND_WARRANTS_De4

NOTE 7 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
NOTE 7 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Number of Warrants Outstanding	7,561,820	5,113,990
Warrants at $0.001 [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$0.00
Number of Warrants Outstanding	383,320
Expiration Date, Warrants	Jan-20
Warrants at $1.50 [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$1.50
Number of Warrants Outstanding	3,721,518
Expiration Date, Warrants	February 2018 to September 2018
Warrants at $1.84 [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$1.84
Number of Warrants Outstanding	35,076
Expiration Date, Warrants	Jan-20
Warrants at $2.02 [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$2.02
Number of Warrants Outstanding	30,755
Expiration Date, Warrants	Jan-20
Warrants at $2.50 [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$2.50
Number of Warrants Outstanding	1,603,600
Expiration Date, Warrants	Jul-15
Warrants at $2.75 [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$2.75
Number of Warrants Outstanding	228,720
Expiration Date, Warrants	August 2019 to September 2019
Warrants at $3.67 [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$3.67
Number of Warrants Outstanding	218,275
Expiration Date, Warrants	December 2018 to January 2019
Warrants at $3.75 [Member]
NOTE 7 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$3.75
Number of Warrants Outstanding	1,340,556
Expiration Date, Warrants	April 2019 to March 2020

NOTE_7_OPTIONS_AND_WARRANTS_De5

NOTE 7 - OPTIONS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Schedule of Stockholders' Equity Note, Warrants or Rights [Abstract]
Warrants Outstanding, Shares	7,561,820	5,113,990
Warrants Outstanding, Weighted-Average Exercise Price	$2.14	$1.71
Warrants Outstanding, Weighted-Average Remaining Contractual Term	3 years	3 years 219 days
Warrants Outstanding, Aggregate Intrinsic Value	$4,300,280	$6,041,436
Vested and expected to vest at March 31, 2015	7,561,820
Vested and expected to vest at March 31, 2015	$2.14
Vested and expected to vest at March 31, 2015	3 years
Vested and expected to vest at March 31, 2015	4,300,280
Exercisable at March 31, 2015	7,561,820
Exercisable at March 31, 2015	$2.14
Exercisable at March 31, 2015	3 years
Exercisable at March 31, 2015	$4,300,280
Grants	2,447,830
Grants	$3.04
Grants	2 years 146 days
Exercised	0
Exercised	$0
Canceled	0
Canceled	$0

NOTE_8_FAIR_VALUE_MEASUREMENT_1

NOTE 8 - FAIR VALUE MEASUREMENT (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Embedded Derivative, Fair Value of Embedded Derivative Liability	$1,242,590	$0
Derivative Liability, Current	$4,097,444	$0

NOTE_8_FAIR_VALUE_MEASUREMENT_2

NOTE 8 - FAIR VALUE MEASUREMENT (Details) - Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (USD $)	3 Months Ended
	Mar. 31, 2015
Warrant [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance, December 31, 2014	$0
Initial fair value of derivative reclassified from equity	4,097,444
Balance, March 31, 2015	4,097,444
Embedded Derivative Financial Instruments [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance, December 31, 2014	0
Initial fair value of derivative reclassified from equity	1,242,590
Balance, March 31, 2015	$1,242,590

NOTE_9_SUBSEQUENT_EVENTS_Detai

NOTE 9 - SUBSEQUENT EVENTS (Details) (USD $)	3 Months Ended	1 Months Ended			0 Months Ended
	Mar. 31, 2015	Apr. 30, 2015	Mar. 31, 2015	Jan. 31, 2015	Apr. 09, 2015	Dec. 31, 2014	Jan. 09, 2013
NOTE 9 - SUBSEQUENT EVENTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	215,000
Class of Warrant or Rights, Exercised	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	0
Series C Preferred Stock [Member] | Subsequent Event [Member]
NOTE 9 - SUBSEQUENT EVENTS (Details) [Line Items]
Conversion of Stock, Shares Issued		131,234
Conversion of Stock, Shares Converted		155
Series C Preferred Stock [Member]
NOTE 9 - SUBSEQUENT EVENTS (Details) [Line Items]
Conversion of Stock, Shares Issued			169,334	42,334
Conversion of Stock, Shares Converted			200	50
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)						$1.50	$2.61
Director [Member] | Subsequent Event [Member]
NOTE 9 - SUBSEQUENT EVENTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					300,000
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)					$3.99
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					7 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights					vesting immediately upon appointment of a new board of directors member
Stock Issued During Period, Shares, Issued for Services		200,000
Subsequent Event [Member] | Stock Issued to Consultant [Member]
NOTE 9 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services		50,000
Subsequent Event [Member]
NOTE 9 - SUBSEQUENT EVENTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)		2.09
Stock Issued During Period, Shares, Conversion of Convertible Securities		84,033
Class of Warrant or Rights, Exercised		130,084
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		1.5
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		10,000